GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Encision Inc (OTCPK:ECIA) » Definitions » Debt-to-EBITDA

Encision (Encision) Debt-to-EBITDA

: -2.16 (As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Encision's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.40 Mil. Encision's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.03 Mil. Encision's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.66 Mil. Encision's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -2.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Encision's Debt-to-EBITDA or its related term are showing as below:

ECIA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -105.47   Med: -0.36   Max: 20.98
Current: -4.81

During the past 13 years, the highest Debt-to-EBITDA Ratio of Encision was 20.98. The lowest was -105.47. And the median was -0.36.

ECIA's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs ECIA: -4.81

Encision Debt-to-EBITDA Historical Data

The historical data trend for Encision's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Encision Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -105.47 2.63 20.98 -4.97

Encision Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -4.59 -2.37 14.58 -2.16

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Encision's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Encision Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Encision's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Encision's Debt-to-EBITDA falls into.



Encision Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Encision's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.576 + 0.508) / -0.218
=-4.97

Encision's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.396 + 1.032) / -0.66
=-2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Encision  (OTCPK:ECIA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Encision Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Encision's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Encision (Encision) Business Description

Traded in Other Exchanges
N/A
Address
6797 Winchester Circle, Boulder, CO, USA, 80301
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities.
Executives
Robert H Fries director 800 FILLMORE ST, DENVER CO 80206
Peter D Geary officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Jason E Johnson officer: VP Sales 17752 WEDGEWOOD LANE, PRIOR LAKE MN 55372
Patrick R Dixon director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Gregory J. Trudel director, officer: CEO 5241 RIMROCK LANE, FORT COLLINS CO 80526
Brian J Jackman director 6797 WINCHESTER CIRCLE, SUITE 100, BOULDER CO 80301
Von Der Lippe Paul director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Denise Baker director 6797 WINCHESTER CIRCLE, BOULDER X1 80301
Vern D Kornelsen director, 10 percent owner 4605 S. DENICE DR, ENGLEWOOD CO 80111
Partners Lllp Cmed 10 percent owner
Patrick W Pace director 3701 SOARING EAGLE, AUSTIN TX 78746
Michael Biggs officer: VP Engineering 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Brad Greathouse officer: VP RA/QA 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Valerie Ray officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
David W Newton director, officer: VP Technology 8099 NORTH 63RD STREET, LONGMONT CO 80503

Encision (Encision) Headlines

From GuruFocus

Encision Receives PPP Financing

By PRNewswire PRNewswire 02-10-2021

Encision Reports Second Quarter Fiscal Year 2020 Results

By PRNewswire PRNewswire 11-06-2019

Encision Reports First Quarter Fiscal Year 2021 Results

By PRNewswire PRNewswire 08-07-2020

Encision Reports First Quarter Fiscal Year 2020 Results

By PRNewswire PRNewswire 08-12-2019

Encision Reports Fourth Quarter Fiscal Year 2021 Results

By PRNewswire PRNewswire 05-19-2021

Encision Completes Private Placement of Common Stock

By PRNewswire PRNewswire 12-20-2018

Encision Reports Third Quarter Fiscal Year 2020 Results

By PRNewswire PRNewswire 02-06-2020